We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

33 hedge funds and large institutions have $1.86M invested in AIM ImmunoTech in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less funds holding

Funds holding: 34 → 33 (-1)

5% less capital invested

Capital invested by funds: $1.97M → $1.86M (-$106K)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
33
Holders Change
-1
Holders Change %
-2.94%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
6
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$15.9K
2
TRCT
Tower Research Capital (TRC)
New York
+$8.39K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$7.09K
4
Verition Fund Management
Verition Fund Management
Connecticut
+$6.57K
5
Renaissance Technologies
Renaissance Technologies
New York
+$4.52K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$45.6K
2
TSS
Two Sigma Securities
New York
-$27.6K
3
VF
Virtu Financial
New York
-$6.29K
4
HF
HRT Financial
New York
-$4K
5
UBS Group
UBS Group
Switzerland
-$1.68K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$875K – – –
BlackRock
2
BlackRock
New York
$311K +$47 +1 +0%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$155K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$89K +$4.52K +97 +5%
State Street
5
State Street
Massachusetts
$76.1K – – –
Verition Fund Management
6
Verition Fund Management
Connecticut
$71.3K +$6.57K +141 +10%
Morgan Stanley
7
Morgan Stanley
New York
$68K -$45.6K -978 -39%
BCM
8
Bridgeway Capital Management
Texas
$47.9K – – –
Northern Trust
9
Northern Trust
Illinois
$37.6K – – –
SWM
10
SeaCrest Wealth Management
New York
$16.3K – – –
Citadel Advisors
11
Citadel Advisors
Florida
$15K +$15.9K +341 New
Bank of New York Mellon
12
Bank of New York Mellon
New York
$11.1K – – –
DS
13
DRW Securities
Illinois
$11K -$1.4K -30 -11%
Jane Street
14
Jane Street
New York
$9.35K +$3.54K +76 +55%
CAPTRUST Financial Advisors
15
CAPTRUST Financial Advisors
North Carolina
$8.8K – – –
FWM
16
ForthRight Wealth Management
Georgia
$8.8K – – –
TRCT
17
Tower Research Capital (TRC)
New York
$8.31K +$8.39K +180 +2,000%
VF
18
Virtu Financial
New York
$7K -$6.29K -135 -46%
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$6.69K +$7.09K +152 New
CB
20
Community Bank
New York
$5.69K – – –
UBS Group
21
UBS Group
Switzerland
$5.66K -$1.68K -36 -22%
DBRC
22
D.B. Root & Company
Pennsylvania
$5.3K – – –
TCM
23
Traynor Capital Management
Pennsylvania
$5.18K – – –
SFG
24
SNS Financial Group
Minnesota
$4.4K – – –
Osaic Holdings
25
Osaic Holdings
Arizona
$697 -$326 -7 -30%
1
2

AIM Hedge Fund Activity: Q4 2023 in Review

33 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q4 2023, worth a combined $1.86M — down 5.4% from $1.97M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of AIM and 3 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 5 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $15.9K. The largest seller was Morgan Stanley, cutting an estimated $45.6K.

  • 33 institutional investors held AIM ImmunoTech (AIM) as of Q4 2023, down from 34 in Q3 2023.
  • Funds reported $1.86M of AIM ImmunoTech stock for Q4 2023, down 5.4% quarter-over-quarter.
  • 3 funds opened new AIM ImmunoTech positions in Q4 2023 and 4 closed out, a net change of -1 holder.
  • The largest AIM ImmunoTech buyer in Q4 2023 was Citadel Advisors, an estimated $15.9K added.
  • The largest AIM ImmunoTech seller in Q4 2023 was Morgan Stanley, an estimated $45.6K sold.

Based on aggregated 13F filings for Q4 2023.